Recent results from the phase III PHILA trial demonstrate a benefit in terms of progression-free survival derived from the addition of pyrotinib to first-line chemotherapy plus trastuzumab in patients with metastatic HER2-positive breast cancer. Dual HER2 blockade with pyrotinib and trastuzumab is an effective therapeutic strategy but might increase the risk of gastrointestinal toxicity; therefore, the risk-to-benefit ratio should be carefully evaluated.

中文翻译：

---

吡咯替尼联合一线曲妥珠单抗和多西他赛治疗 HER2 阳性转移性乳腺癌患者：一种新的治疗选择？

III 期 PHILA 试验的最新结果表明，一线化疗方案中添加吡咯替尼加曲妥珠单抗对转移性 HER2 阳性乳腺癌患者的无进展生存期有好处。使用吡咯替尼和曲妥珠单抗双重 HER2 阻断是一种有效的治疗策略，但可能会增加胃肠道毒性的风险；因此，应仔细评估风险收益比。